1-s2.0-S259001882300014X-main.pdf (1.05 MB)
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
journal contributionposted on 2023-07-25, 14:08 authored by C Gerard, B Shum, P Nathan, S Turajlic
Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoint inhibitors is associated with poor outcomes in metastatic uveal melanoma (mUM). Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. This review summarises the existing and emerging immuno-oncology approaches for the treatment of mUM, and biomarkers of response and resistance to the same. Finally, we propose future research directions that could maximise treatment benefit to a wider pool of patients with UM.
Crick (Grant ID: CC2044, Grant title: Turajlic CC2044)